While the rest of the health care system is moving toward paying for value, payments for drugs largely continue to be stuck in a 20th century construct that focuses on price, regardless of the health outcomes of each patient. This lack of payment innovation is particularly damaging in an era where on the horizon new treatments and cures promise great benefit for consumers, but also bring great upfront costs for individuals, employers, and governments at every level. This article proposes a new path forward.

Source: Health Affairs Blog